Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long Search Ends For Sanofi As It Buys Universal Medicare's Nutraceutical Brands In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - French drug maker Sanofi's long search for high-growth OTC brands in India finally materialized as it announced the acquisition of Mumbai-headquartered Universal Medicare Pvt. Ltd.'s nutraceutical businesses
Advertisement

Related Content

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)
GSK CEO Calls For Change In Business Model As World Power Moves To Emerging Economies
GSK CEO Calls For Change In Business Model As World Power Moves To Emerging Economies
Emerging Views On Emerging Markets: Morgan Stanley Global Healthcare Conference
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Danone Gets Second Time Lucky, Buys Wockhardt's Nutrition Brands That Abbott Had Won And Lost
Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 2 of 2)
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 2 of 2)
Sanofi-Aventis India Managing Director Shailesh Ayyangar On Building Infrastructure To Bring Affordable Drugs To Patients In Rural Markets: An Interview With PharmAsia News (Part 2 of 2)
Advertisement
UsernamePublicRestriction

Register

SC078832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel